Standard Biotools (LAB) Consolidated Net Income (2010 - 2026)

Standard Biotools (LAB) has 17 years of Consolidated Net Income data on file, last reported at $141.7 million in Q1 2026.

• Consolidated Net Income for Q1 2026 came in at $141.7 million, up 5420.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $128.3 million (up 468.06% YoY), and the FY2025 annual result was -$16.1 million, up 66.48% from the prior year.
• Consolidated Net Income improved to $141.7 million in Q1 2026 per LAB's latest filing, from $5.4 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at $141.7 million in Q1 2026 and troughed at -$76.3 million in Q1 2022.
• A 5-year average of -$8.5 million and a median of -$15.8 million in 2025 frame the typical range for Consolidated Net Income.
• The sharpest annual moves came in 2022 and 2026: Consolidated Net Income tumbled 305.82% in 2022, then soared 5420.84% in 2026.
• A 5-year view of Consolidated Net Income shows it stood at -$2.0 million in 2022, then soared by 1156.13% to $20.7 million in 2023, then slumped by 133.36% to -$6.9 million in 2024, then soared by 178.01% to $5.4 million in 2025, then soared by 2532.74% to $141.7 million in 2026.
• Business Quant data shows LAB's Consolidated Net Income at $141.7 million in Q1 2026, $5.4 million in Q4 2025, and -$3.0 million in Q3 2025.